Eric Lefkofsky: An Innovative Health Leader.

With a net worth of over 2.5 billion dollars and currently at position 359 on the Forbes 400, Eric Lefkofsky is a self-made billionaire, and the chief executive officer comes founder of the Tempus; a medical solution provider with the primary aim of treating cancer.

Eric studied at the University of Michigan in which he was awarded honors and two years later a Juris doctor from the law school. Besides the Tempus, Lefkofsky is also the chair of Groupon, a co-founder of the VC firm lightbanks, a company that has focused on making investments in other companies and the co-founder of uptake, a company that manages other companies safety and operations by using data science.

Together with his wife, Liz Lefkofsky, Eric formed the Lefkofsky family foundation, a family foundation that has tasked itself with developing solutions to the human life through integrated programs and research.

Their organization is mainly based in Chicago and have focused on activities, for instance, supporting young children, providing scholarship programs and emphasizing on financial education through an innovative program called money thing.

Besides that, he has offered a lot of support to the University of Michigan and the De Paul University.

Health is a crucial issue; the Eric Lefkofsky foundation has fully supported research on the various treatment for leukemia, cancer, and various cardiovascular diseases, for instance, Alzheimer and celiac disease Through monetary donations for example in 2015, they contributed over 780000 us dollars to the Texas university cancer center.

The art and culture industry and the technology industry have benefited from the foundation, for instance, a 7 million dollar contribution made to the Stephen wolf theater company and various museums.

Together with Google, they created the 1871 fetch, an organization with the primary function of encouraging and increasing the number of female techpreneurs in the field. Eric Lefkofsky is responsible for the fast-growing accelerated disruption, a business development that has focused on keeping in pace with the various technological advancement.

This concept has been able to identify the major industries to develop besides helping found various technology startups. Accelerated disruption emphasizes first on choosing the right market for innovation and then using automation for tasks that can quickly be done while ensuring the same level of quality.

To Read More Click Here

Leadership and Contribution of Clay Siegall

Clay Siegall holds a B.S in Zoology from the University of Maryland and a PHD in genetics from George Washington University. In 1998 , he founded Seattle Genetics as the company president. He was also the chairman of the Board of Directors and the chief executive officer.

It should be noted that under his leadership, the company has established multiple channels of anti-body based cancer therapies. Seattle Genetics managed to make the longest strides under his leadership more than under any other executive in the recent past.

Dr. Clay has guided the company’s fund raising activities that have seen the company raise more than $675 million via public and private funding. He has also served with various companies such as Bristol-Myers Squibb Pharmaceutical Research Institute, National Cancer Institute and the National Institutes of health.

Seattle Genetics is the supreme biotech firm in the region. Its headquarter is made of a green triangular sculpture made of Lego bricks that act as a simplified replica of a human antibody. Throughout its time, the company has been devoted to researching and controlling the antibodies and also packaging them into drugs.

The company boasts of many employees that have all been working hard to anchor the company through the prevailing challenges in the health sector and ensure it succeeds in its fight against all cancer related issues.These grand ambitions by the company and its membersmay sore the company to greater heights such as growing to become a pharmaceutical company.

Under the leadership of Mr.Clay Siegall, the company has developed a forerunner drug known as Adcetris. It helps in treating Hodgkin lymphoma, a cancer of the lymph system that can advance to other organs of the body. Mr. Clay aspires to move the company beyond focusing on drug development to handling all the difficulties of worldwide marketing of the newer drugs.

He declares the company is emerging globally and turning to a multiproduct-oriented company. It has made numerous sales throughout the business cycles and also opened multiple branches in different parts of the world’s courtesy of one Clay Siegall.

Food and Drug administration has approved the drug to treat lymphoma. Out of its 11 drugs, four attract a great potential for fast sales. Despite of the worrying economic and political climates, Clay stands strong and hopeful for the success of the activities of the company. The company continues to find for long time solutions and positive treatments for cancer and its complications.